ENDRA Life Sciences Inc. and VGI Health Technology Limited announce the signing of a collaboration agreement to incorporate ENDRA's proprietary TAEUS technology to support patient screening and biomarker measurement during VGI's upcoming Phase 2 study of IVB001 in Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.02 AUD | -33.33% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 1.85M | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.49% | 21.6B | |
-12.38% | 22.31B | |
-6.77% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- VTL Stock
- News VGI Health Technology Limited
- ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study